XTX Topco Ltd Acquires New Stake in Kodiak Sciences Inc. (NASDAQ:KOD)

Key Points

• XTX Topco Ltd acquired 45,089 shares of Kodiak Sciences Inc., valued at approximately $126,000, increasing its ownership to 0.09% of the company.
• Several hedge funds have also increased their stakes in Kodiak Sciences, with Nantahala Capital Management LLC boosting its stake by 287.2% during the fourth quarter.
• Kodiak Sciences reported a quarterly loss of ($1.03) EPS, missing analysts' estimates, and has been given a new price target range of $7.00 to $15.00 by different research firms.

XTX Topco Ltd acquired a new stake in shares of Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 45,089 shares of the company's stock, valued at approximately $126,000. XTX Topco Ltd owned 0.09% of Kodiak Sciences at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. The Manufacturers Life Insurance Company acquired a new position in shares of Kodiak Sciences during the fourth quarter valued at approximately $902,000. Vontobel Holding Ltd. acquired a new position in shares of Kodiak Sciences during the first quarter valued at approximately $28,000. GSA Capital Partners LLP increased its stake in shares of Kodiak Sciences by 163.6% during the first quarter. GSA Capital Partners LLP now owns 205,833 shares of the company's stock valued at $577,000 after acquiring an additional 127,748 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Kodiak Sciences by 5.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 521,237 shares of the company's stock valued at $5,186,000 after acquiring an additional 26,058 shares during the period. Finally, Nantahala Capital Management LLC increased its stake in shares of Kodiak Sciences by 287.2% during the fourth quarter. Nantahala Capital Management LLC now owns 266,613 shares of the company's stock valued at $2,653,000 after acquiring an additional 197,756 shares during the period. Institutional investors and hedge funds own 89.06% of the company's stock.

Kodiak Sciences Stock Performance

Kodiak Sciences stock opened at $10.04 on Friday. The firm has a market cap of $529.71 million, a price-to-earnings ratio of -2.64 and a beta of 2.41. Kodiak Sciences Inc. has a 1 year low of $1.92 and a 1 year high of $11.60. The firm's 50 day moving average price is $5.45 and its two-hundred day moving average price is $4.42.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by ($0.02). As a group, equities analysts predict that Kodiak Sciences Inc. will post -3.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on KOD shares. Barclays raised their price objective on shares of Kodiak Sciences from $4.00 to $7.00 and gave the company an "underweight" rating in a research note on Thursday. JPMorgan Chase & Co. upgraded shares of Kodiak Sciences from an "underweight" rating to a "neutral" rating and set a $15.00 price target on the stock in a research report on Thursday.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.

Want to see what other hedge funds are holding KOD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kodiak Sciences Inc. (NASDAQ:KOD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.